German and UK researchers cut time to sepsis diagnosis
Researchers from German Fraunhofer IGBI have used next-generation sequencing (NGS) to diagnosis sepsis from tiny amounts of microbial DNA in the blood.
ADVERTISEMENT
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 2185 entries already.
Entries by Thomas Gabrielczyk
Sustainable DNA extraction 70% less plastic, 50% less costs
BioEcho develops single-spin and 96-well kits for the isolation of DNA from different starting materials. In contrast to common bind-wash-elute procedures, their proprietary EchoLUTION single-step technology avoids the use of inhibitory or harmful process reagents and does not require washing steps. 90% of the disposal costs are saved as well as more than 40% of the pipet tip consumption costs. The inhibitor-free DNA enables lowered time-to-result in enzyme-dependent genomic analyses such as PCR or NGS.
IMI launches €45m call for coronavirus emergency
The Innovative Medicines Initiative (IMI) has announced a €45m funding for the development of therapeutics and diagnostics to tackle coronavirus outbreaks.
Immunocore Ltd raises US$130m in Series B round
With the financing led by General Atlantic, the British company wants to expand a novel platform and advance its ImmTAX pipeline to the clinic.
Vitamin C may boost checkpoint inhibitor efficacy
High amounts of injected vitamin C may delay the growth of many types of tumours and boost the anticancer power of immune checkpoint therapies, report Italian oncologists.
Roche grabs Bicycle Therapeutics’ platform
Roche AGs has paid US$30m upfront in a potential US$1.7bn deal to get access to Bicycle Therapeutics plc’s technology platform to target immune checkpoints.
Human iPSC derived neurons for research and HTS
Widespread use of human induced pluripotent stem cell (hiPSC) derived mature cell types is restricted by complex differentiation protocols and inefficient reprogramming methods. By applying a novel gene engineering approach, opti-oxTM, to cellular reprogramming these restrictions have been largely overcome. This proprietary technology enables precise reprogramming and homogeneous differentiation of entire stem cell cultures into any desired cell type.
Microglia inhibitor stops neuronal cell death after TBI
Post-Brexit budget drives cuts in Horizon Europe
Negotiations of the EU Council on the EU’s seven-year budget have failed, putting R&D funding at risk for significant cuts.
Royal DSM acquires Glycom A/S for €765m
Royal DSM NV has entered the growing market of human milk oligosaccharides (HMO) taking over the producer of recombinant 2′-fucosyl lactose, Danish Glycom A/S.